Abstract |
We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical results are presented in the preceding companion paper. Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans (median 80% reduction, p = 0.0082) and appearance of new lesions. In addition, there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups (mean group difference of 23%, p = 0.001). These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients.
|
Authors | D W Paty, D K Li |
Journal | Neurology
(Neurology)
Vol. 43
Issue 4
Pg. 662-7
(Apr 1993)
ISSN: 0028-3878 [Print] United States |
PMID | 8469319
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Adult
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Interferon-beta
(therapeutic use)
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis
(diagnosis, therapy)
- Recurrence
- Treatment Outcome
|